Physician profile
Seema Singhal
NPI 1013940501
$65,077.67
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55K · 2020: $9,699 · 2022: $362.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $24,793.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20,538.93 | 2019-2020 | |
| Celgene Corporation | $12,161.99 | 2019 | |
| Glaxosmithkline, LLC. | $6,000.00 | 2020 | |
| Janssen Research & Development, LLC | $1,128.12 | 2019 | |
| Menarini Silicon Biosystems, INC. | $361.58 | 2022 | |
| Emd Serono, INC. | $93.23 | 2019 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seema Singhal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.